指南与共识头颈外科咽喉与嗓音小儿耳鼻咽喉

全身性贝伐珠单抗治疗呼吸道乳头状瘤病:国际共识声明

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement.
指南 / 共识 · Laryngoscope · 2021-01-06

本研究采用德尔菲法调查,由12个国家70位多学科专家参与,旨在就全身性贝伐珠单抗治疗复发性呼吸道乳头状瘤病(RRP)的关键点达成共识。共识别189个条目,在患者特征(9项)、疾病特征(10项)、治疗中心特征(22项)和既往检查特征(18项)方面达成共识。该共识为临床医生和中心提供使用该治疗的起点和框架。

要点

  • 国际共识支持全身性贝伐珠单抗用于复发性呼吸道乳头状瘤病的治疗。
  • 共识涵盖患者特征、疾病特征、治疗中心特征和既往检查特征。
  • 共识可为标准化给药和联合治疗方案提供框架。

核心结论

  • 该共识声明为希望提供全身性贝伐珠单抗治疗RRP的临床医生和中心提供了有用的起点和框架。

研究设计与样本

  • 基于德尔菲法的调查系列,建立了具有使用全身性贝伐珠单抗治疗RRP经验的多学科、多机构专家小组。

主要发现

  • 国际专家小组由来自12个国家的70位专家组成,代表小儿和成人耳鼻咽喉科、血液/肿瘤科、感染性疾病科、小儿外科、家庭医学和流行病学。
  • 共识别189个条目,在患者特征(9项)、疾病特征(10项)、治疗中心特征(22项)和既往检查特征(18项)方面达成共识。

关键数值与推荐

  • 在患者特征、疾病特征、治疗中心特征和既往检查特征四个领域达成共识的具体条目数分别为9、10、22和18项。

临床怎么用

  • 临床医生和中心可参考该共识框架提供全身性贝伐珠单抗治疗RRP,并评估其实践组成。
  • 标准化给药系统可能促进研究努力并提供给药方案,有助于塑造全身性贝伐珠单抗在早发型或较轻疾病表型患者中的最佳实践应用。

局限性

  • 证据等级为5级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. STUDY DESIGN: Delphi method-based survey series. METHODS: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up. RESULTS: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18). CONCLUSION: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. LEVEL OF EVIDENCE: 5 Laryngoscope, 131:E1941-E1949, 2021.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Sidell DR, Balakrishnan K, Best SR, et al. Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. Laryngoscope. 2021. PMID: 33405268. doi:10.1002/lary.29343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。